Time is short.
I hope that you might be interested in this article regarding the FDA's review of an innovative MS therapy. The appeal is at a critical stage that could be influenced by the views of MS doctors and patients. If you have a view on this article - favorable or unfavorable - or on whether or not Lemtrada should be one option for MS doctors treating their patients, then please consider writing a letter to the editor.
Mr. Timothy Lemmer
Letters Editor, The Wall Street Journal
1211 Avenue of the Americas
New York, NY 10036
There is a 300 word limit. Please include the date (Friday, January 17, 2013), headline (The FDA Nixes a Pathbreaking Drug for MS) and page number of article (A13), as well as your name and the city where you are located.
One important attribute of the FDA's review was the total exclusion of MS experts from their decision-making process. So, now could be a useful time for experts to speak up. For something to think about, here are some recent quotes from three such experts.
Disclosure: I am long GCVRZ.
Additional disclosure: Chris DeMuth Jr is a portfolio manager at Rangeley Capital, a partnership that invests with a margin of safety by buying securities at deep discounts to their intrinsic value and unlocking that value through corporate events. In order to maximize total returns for our partners, we reserve the right to make investment decisions regarding any security without further notification except where such notification is required by law. Image by David G Klein; more of his art available here: www.illoz.com/kleinart/